| answer text |
<p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered
Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction
in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained,
the lifetime quality-adjusted life year gain of these services was estimated at 1.49,
which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In
response to these initial evaluation findings, NHS England expanded the T1DE programme,
supporting provision of new services in an additional five sites from September 2022,
expanding coverage to more areas of the country. It is expected that these services
will generate further evaluation data to consolidate these early findings, which can
be used to inform national and local policy decisions.</p><p>NHS England is drawing
on learning from existing T1DE services, other emerging evidence and the findings
of the recent parliamentary inquiry, to ensure all areas of the country are supported
to improve care for those identified as having T1DE. The emergence of these future
plans are subject to future spending review settlements for the NHS and level of funding
from the NHS England budget allocated to T1DE.</p><p>NHS England are also working
closely with the first wave of pilot sites including London to ensure that the newer
services can benefit from their learning and experience when considering local funding
options in advance of March 2025, when the national funding for the five new sites
will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated
care boards to develop local funding arrangements through the provision of evaluation
data, a national programme of support workshops, and an online platform to share learning
and good practice.</p>
|
|
